Press releases

Read more:


Archive per year

Nanologica Announces the Nomination Committee for the 2022 Annual General Meeting

In accordance with the decision taken at the annual general meeting on May 27, 2021, the three largest shareholders as of September 30, 2021 have been contacted by the chairman of the board and been offered to appoint a member each to the nomination committee of Nanologica AB. The three largest shareholders as of September 30, 2021 have each appointed one representative so that the nomination committee for the annual general meeting 2022 consists of

Read more »

Nanologica Closes NIC-001

Nanologica AB has decided to close the project with the drug candidate NIC-001 for the treatment of gastroparesis before the planned clinical study begins, in order to focus the company’s resources on the continued development of the inhalation platform NLAB Spiro®. The closure of the project is a result of the company’s strategy in the drug development business area being refined to focus on inhalation and respiratory diseases, and because the commercial conditions for NIC-001

Read more »

Nanologica Recruits Chief Scientific Officer

Nanologica has recruited Gary Pitcairn as Chief Scientific Officer as part of the strategy to increase the focus on inhalation and respiratory diseases, as well as to accelerate the development of the company’s technology platform for inhalation, NLAB Spiro®. Nanologica is exploring new possibilities within inhalation and respiratory diseases and has recruited Gary Pitcairn as the company’s first Chief Scientific Officer. Gary, who during 2021 has been one of Nanologica’s scientific advisors for inhalation, will

Read more »

First Tox Study for Nanologica’s Inhalation Platform NLAB Spiro® Completed

Nanologica has completed the first study within the tox program for the inhalation platform NLAB Spiro®. The program now continues with further studies. NLAB Spiro® is Nanologica’s technology platform for inhalation. To validate the safety of the platform, toxicity studies are conducted in several steps and the first study has now been completed. Results from the sub-study are expected to be presented during the third quarter. During the second half of the year, the program

Read more »

Exercise of Rights in Nanologica’s Stock Option Program

In Nanologica’s stock option program 2018/21 exercise of rights in Nanologica’s stock option program has increased the number of shares in the company by 371,346 to 28,165,826 shares. As a result, the share capital increases to SEK 11,548,761. At Nanologica’s Annual General Meeting on May 31, 2018, it was resolved to establish an incentive program of a maximum of 484,883 stock options for the company’s employees. Each option entitles the holder to subscribe for one

Read more »

Nanologica’s patent granted in Australia

The Australian Patent Office has granted Nanologica’s patent titled ”A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery”. The patent protects the company’s technology platform NLAB Spiro® by giving exclusivity on methods for producing particles loaded with active pharmaceutical ingredients for lung delivery, among other dosage forms. ” This patent was granted in Europe last year and it is pleasing that we

Read more »